Evidence map›Paper›PMID 33743151›Full record

ArticleCNS drugs2021

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.

Anthony T Reder, Diego Centonze, Maria L Naylor, Anjali Nagpal, Rajani Rajbhandari, Arman Altincatal, Michelle Kim, Aaron Berdofe, Maha Radhakrishnan, Eunice Jung and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 6 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 6 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  4. Pooled it
  5. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Anthony T RederDepartment of Neurology and Brain Research Institute, University of Chicago, Chicago, IL, USA. areder@neurology.bsd.uchicago.edu.ORCID http://orcid.org/0000-0002-6423-1495
Diego CentonzeLaboratory of Synaptic Immunopathology, Department of Systems Medicine, Tor Vergata University, Rome, Italy.ORCID http://orcid.org/0000-0002-8390-8545
Maria L NaylorBiogen, Cambridge, MA, USA.
Anjali NagpalBiogen, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2711-445X
Rajani RajbhandariBiogen, Cambridge, MA, USA.
Arman AltincatalBiogen, Cambridge, MA, USA.
Michelle KimBiogen, Cambridge, MA, USA.
Aaron BerdofeBiogen, Cambridge, MA, USA.
Maha RadhakrishnanBiogen, Cambridge, MA, USA.
Eunice JungBiogen, Cambridge, MA, USA.
Alfred W SandrockBiogen, Cambridge, MA, USA.
Karen SmirnakisBiogen, Cambridge, MA, USA.
Catrinel PopescuBiogen Idec, Maidenhead, UK.
Carl de MoorBiogen, Cambridge, MA, USA.
Biogen (United States) · USAllen Institute for Brain Science · USBiogen (United Kingdom) · GBUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed these risks in patients with MS (PwMS).

objectiveThe objective of this study was to describe the overall risk of coronavirus disease 2019 (COVID-19) infection, severe disease course, and potential population-level predictors of COVID-19 infection in PwMS, and to provide a context using a cohort of patients with systemic lupus erythematosus (SLE). In addition, the association of different MS DMTs with the incidence and clinical course of COVID-19 was evaluated. Safety data from the Biogen Global Safety Database are also presented on reported cases of COVID-19 in patients treated with Biogen MS therapies.

methodsThe IBM

results30,478 PwMS with an open DMT prescription were identified within Explorys; 344 were COVID-19 positive. The most significant risk factors for acquiring COVID-19 were comorbidity score ≥ 1, body mass index ≥ 30, and Black/African ancestry. Similar risk factors were also identified for patients with SLE. Patients with MS were less likely to develop COVID-19 when treated with interferons (0.61%) and glatiramer acetate (0.51%), vs all other MS DMTs (both p < 0.001); anti-CD20 therapy was associated with the highest risk (3.45%; p < 0.0001). In the Biogen Global Safety Database, we identified 1217 patients who were COVID-19 positive treated with intramuscular interferon beta-1a, peginterferon beta-1a, natalizumab, dimethyl fumarate, diroximel fumarate, or fampridine.

conclusionsComorbidities, obesity, and Black/African ancestry, but not age, were associated with a higher risk of SARS-CoV-2 infection in PwMS. Interferons and glatiramer acetate were associated with a reduced COVID-19 risk, whereas anti-CD20 therapies were associated with an increased risk, within the treated MS cohort. COVID-19 safety reports for patients receiving Biogen MS therapies were consistent with the Explorys database and MS literature, illustrating the replicability and power of this approach.

Indexed as

AdolescentAdultAgedAged, 80 and overAlemtuzumabAzathioprineBlack or African AmericanCladribineComorbidityCOVID-19CrotonatesCyclophosphamideCyclosporineDatabases, FactualDimethyl FumarateFemaleAlemtuzumabAzathioprineCladribineCrotonatesCyclophosphamideCyclosporineDimethyl FumarateFingolimod HydrochlorideHydroxybutyratesImmunologic FactorsImmunosuppressive AgentsInterferon-betaMethotrexateMitoxantroneMycophenolic AcidNatalizumabNitrilesRituximabteriflunomideToluidines

Identifiers

PMID33743151
PMCPMC7980129
OpenAlexW3139311115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.